Scenari attuali nell’ambito del trattamento del linfoma a grandi cellule B (LBCL) refrattario alla prima linea

2745, ASH2025. 25. Sim AJ, Jain MD, Figura NB, et al. Radiation therapy as a bridging strategy for relapsed/refractory B-cell lympho- ma before chimeric antigen receptor T-cell therapy. Int J Radiat Oncol Biol Phys 2019; 105: 1044-54. 26. Wright CM, LaRiviere MJ, Baron JA, et al. Bridging radia- tion therapy before commercial chimeric antigen recep- tor T-cell therapy for relapsed or refractory aggressive B-cell lymphoma. Blood Adv 2022; 6: 4850-60. 27. Nagler A, Perriello VM, Falini L, Falini B. How I treat re- fractory/relapsed diffuse large B-cell lymphomas with CD19-directed chimeric antigen receptor T cells. Br J Haematol 2023; 201: 396-410. 28. Luminari S, et al. Overcoming barriers to referral for CAR T-cell therapy in patients with non-Hodgkin aggressive B-cell lymphomas: a Delphi Consensus. Cytotherapy 2025; 27: 1316-25. 29. Tao Z, Chyra Z, Kotulová J, et al. Impact of T cell charac- teristics on CAR-T cell therapy in hematological malig- nancies. Blood Cancer J 2024; 14: 213. 30. Locke FL, Siddiqi T , Jacobson CA, et al. Impact of vein- to-vein time in patients with R/R LBCL treated with axi- cabtagene ciloleucel. Blood 2025; 9: 2663-776. 31. Lee DW, Santomasso BD, Locke FL, et al. ASTCT Con- sensus grading for cytokine release syndrome and neuro- logic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019; 25: 625-38. 32. Yakoub-Agha I, Chabannon C, Bader P , et al. Manage- ment of adults and children undergoing CAR t-cell ther- apy: best practice recommendations of the European So- ciety for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica 2020; 105: 297-316. Indirizzo per la corrispondenza: Stefania Bramanti E-mail: stefania.bramanti@cancercenter.humanitas.it - Copyright - Il Pensiero Scientifico Editore downloaded by IP 175.193.85.86 Wed, 08 Jul 2026, 19:47:43